Highest-materiality recent filing
Picard Medical posts investor presentation; no financials or material updates disclosed
Picard Medical (NYSE American: PMI) published an investor presentation dated August 19, 2026.
NYSE American accepts Picard Medical's compliance plan; listing continues through Nov 2027
NYSE American accepted compliance plan under Sections 1003(a)(i) and (ii) due to low equity and losses.
Picard Medical announces 1-for-50 reverse stock split to maintain NYSE American listing
Reverse stock split at 1-for-50 effective 5:00 PM ET on July 31, 2026.
Picard Medical shareholders approve reverse stock split and Class B super-voting shares
Reverse stock split approved at ratio 1:15 to 1:50; board to set exact ratio and timing.
Picard Medical Q1 revenue up 85% YoY; gross margin improves to 24%
Revenue for first three months of 2026 increased 85% YoY; U.S. revenue up 116%.
Picard Medical amends 8-K to correct Dr. Joe Xiao's board committee appointments
Dr. Joe Xiao appointed to Board effective June 23, 2026.
Filing includes transcript of pre-recorded presentation covering business performance, product development, and manufacturing initiatives.
Revenue increased 85% YoY; US revenue up 116%; gross margin improved to 28% from year-end 2025.
Picard Medical appoints Dr. Joe Xiao to Board of Directors, effective June 23, 2026
Dr. Xiao appointed to Board with term expiring at 2026 annual meeting of stockholders.
Picard Medical CEO Patrick Schnegelsberg steps down; Chairman Richard Fang named interim CEO
Patrick NJ Schnegelsberg resigned as CEO and board member effective June 18, 2026; departure not related to any disagreement.
Picard Medical terminates CFO Bernard Skaggs; appoints Georgina Smith as CAO
Bernard Skaggs terminated as CFO, effective June 1, 2026.
Picard Medical Q1 revenue up 85%, gross margin 24%; NYSE listing notice received
Q1 2026 revenue $1.2M (+85% YoY); gross profit margin 24% vs. -58% in Q1 2025.
Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices
Revenue $1.2M (+85% YoY); gross profit $0.3M (24% margin) vs gross loss of $0.4M in Q1 2025.
Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity
Gross proceeds of $5.0M from sale of ~16.7M shares (or pre-funded warrants) and Series A/B warrants at $0.30 per unit.
Picard Medical prices $5M offering, exchanges high-price warrants for new $0.35 warrants
Gross proceeds ~$5M from selling 16.67M shares and common warrants at $0.30/unit.
Picard Medical Q1 preliminary revenue up 79.9% to $1.1M; driven by STAH sales
Preliminary unaudited revenue of $1.1M for Q1 2026 vs $0.6M in Q1 2025, a 79.9% increase.
Picard Medical closes $500K convertible note with Quick Capital; 80K origination shares issued
Issued convertible note with $555,556 principal; funded $500,000 after $55,556 OID; cash received $490,000 after expenses.
Picard Medical FY2025 revenue $4.94M (+12.5% YoY); U.S. rev +33.5%
Revenue $4.94M (+12.5% YoY); U.S. revenue +33.5% to 88.25% of total.
Picard Medical FY2025 revenue up 12.5% to $4.9M, net loss widens to $27.0M
Revenue $4.94M (+12.5% YoY); product revenue $4.75M, 96% of total.
Picard Medical to present preclinical data on Emperor Total Artificial Heart at ACC.26
Poster presentation on March 29, 2026, featuring early preclinical data on fully implantable Emperor Total Artificial Heart.
SynCardia TAH bridges patient for 119 days to successful heart transplant at UCSF Health
Male patient in his twenties with biventricular heart failure received SynCardia TAH on Nov 15, 2025.
Patient supported 1,636 days on SynCardia Total Artificial Heart before transplant
29-year-old patient implanted Sept 2, 2021 with SynCardia Total Artificial Heart.
Picard Medical shareholders authorize share increase to 330M and stock issuance for financing
Special meeting held March 10, 2026; 57.16% of 73.7M shares represented.
Picard Medical schedules Annual Business Update webcast for March 25, 2026
Webcast will review FY and Q4 2025 financial results and provide a business update on commercial and strategic priorities.
Picard Medical to feature SynCardia TAH on FOX Business BTV segment March 14
Picard Medical (NYSE American: PMI) will appear on BTV Business Television on FOX Business on March 14, 2026 at 5:00 p.m. ET.
Picard Medical to present preclinical Emperor TAH data and clinical outcomes at THT 2026
Dr. Andre Simon to deliver three presentations at THT 2026 conference (Mar 2-4, Boston) on SynCardia TAH and Emperor system.
Participates in inaugural Hands-On Training Day at Technology and Heart Failure Therapeutics 2026 in Boston on March 1, 2026.
Over 2,100 STAH implants across 27 countries; only FDA-approved total artificial heart.
Picard Medical launches podcast series on SynCardia heart and Emperor device
Press release announces 'Cruxx to MedTech Podcast' exploring SynCardia Total Artificial Heart (STAH) and next-gen Emperor device.
Issued $15M initial senior secured notes due Dec 26, 2028, at 0% annual interest, with option for up to $35M additional.
Picard Medical rings NYSE Opening Bell on Dec 18, 2025, marking public company milestone
CEO Patrick NJ Schnegelsberg and management team to ring Opening Bell at NYSE on December 18, 2025.
Patient at IVDK Dedinje Hospital (Belgrade, Serbia) reached 2,900 days on SynCardia Total Artificial Heart, longest ever recorded.
Emperor TAH uses identical blood-contacting materials as FDA-approved SynCardia STAH, replaces pneumatic driver with electromechanical system.
Picard Medical CEO to present Emperor TAH data at CSI Focus D-HF in Frankfurt
CEO Patrick NJ Schnegelsberg presenting on December 6, 2025 at 13:00 CET in the 'Durable Mechanical Circulatory Support' session.
Picard Medical to present Emperor TAH in vitro data at ISMCS 2025 in Vienna
Duffy Elmer to present benchtop performance data on the fully implantable Emperor Total Artificial Heart on Dec 4, 2025.
Picard Medical Secures $1M Bridge Loan from Chairman Affiliate at 6% Interest
$1M unsecured promissory note issued to Fang Family Fund, LLC, an affiliate of Chairman Richard Fang.
SynCardia implants Emperor Total Artificial Heart in first in vivo study
Three pre-clinical models successfully implanted with the Emperor TAH; all taken off bypass without issues.
Picard Medical Q3 revenue up 35% to $1.19M; IPO nets $15.5M in September
Revenue $1.19M (+35% YoY); gross loss narrowed 81% to $0.13M; operating loss $3.36M vs $3.77M.
Picard Medical issues statement on stock volatility, cites no undisclosed material change
Picard Medical (NYSE American: PMI) states no undisclosed material change causing recent stock volatility.
Stockholders approve amendment to 2021 equity incentive plan, increasing share reserve to 18M
Amendment increases aggregate shares available to 18,000,000 from an unspecified prior limit; adds warrants as award type.
Picard Medical closes full over-allotment option in IPO, raising additional $2.55M
Underwriters exercised option for 637,500 shares at $4.00/share on Sep 5, 2025.
Picard Medical prices $17M IPO at $4/share; commences trading on NYSE American under PMI
4,250,000 shares sold at $4.00 for $17M gross proceeds; over-allotment option for 637,500 additional shares.
The Board appointed Richard Fang, Ph.D., 60, as the Company's Interim Chief Executive Officer, effective as of the Separation Date.
On June 17, 2026, Patrick NJ Schnegelsberg notified Picard Medical, Inc. (the "Company") of his decision to step down as Chief Executive Officer and as a member of the Board of Directors of the Company (the "Board"), effective June 18, 2026
The Board of Directors of the Company appointed Georgina Smith, 54, as the Company’s Chief Accounting Officer, effective June 1, 2026.
Bernard Skaggs was terminated as the Chief Financial Officer of Picard Medical, Inc. (the “Company”), effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event other_material